A phase 2 study of sitravatinib in metastatic, pre-treated, triple negative breast cancer, NCT # 04123704

被引：0
|
作者：
Shafaee, Maryam Nemati
Otte, Kristen
Neill, Nicholas J.
Osborne, Kent C.
Westbrook, Thomas F.
Hilseneck, Susan
Ellis, Matthew J.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT2-28-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-28-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Anlotinib in pre-treated metastatic HER2-negative breast cancer: A phase II, single-arm clinical study
    Hu, Nanlin
    Luo, Yang
    Wang, Jiayu
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Xu, Binghe
    Yuan, Peng
    CANCER RESEARCH, 2020, 80 (04)
  • [2] Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study
    Stathopoulos, GP
    Tsavdaridis, D
    Malamos, NA
    Rigatos, SK
    Kosmas, C
    Pergantas, N
    Stathopoulos, JG
    Xynotroulas, J
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (05) : 487 - 491
  • [3] Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer
    Seo, Hee Yeon
    Lee, Hyun Joo
    Woo, Ok Hee
    Park, Kyong Hwa
    Woo, Sang Uk
    Yang, Dae Sik
    Kim, Ae-Ree
    Lee, Jae-Bok
    Lee, Eun Sook
    Kim, Yeul Hong
    Kim, Jun Suk
    Seo, Jae Hong
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (02) : 360 - 365
  • [4] Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer
    Hee Yeon Seo
    Hyun Joo Lee
    Ok Hee Woo
    Kyong Hwa Park
    Sang Uk Woo
    Dae Sik Yang
    Ae-Ree Kim
    Jae-Bok Lee
    Eun Sook Lee
    Yeul Hong Kim
    Jun Suk Kim
    Jae Hong Seo
    Investigational New Drugs, 2011, 29 : 360 - 365
  • [5] Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study
    G. P. Stathopoulos
    D. Tsavdaridis
    N. A. Malamos
    S. K. Rigatos
    Ch. Kosmas
    N. Pergantas
    J. G. Stathopoulos
    J. Xynotroulas
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 487 - 491
  • [6] Anlotinib has good efficacy and low toxicity: a phase Ⅱ study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
    Nanlin Hu
    Yiran Si
    Jian Yue
    Tingting Sun
    Xue Wang
    Zhuqing Jia
    Songlin Gao
    Qiao Li
    Yang Shao
    Jiayu Wang
    Yang Luo
    Fei Ma
    Binghe Xu
    Peng Yuan
    Cancer Biology & Medicine , 2021, (03) : 849 - 859
  • [7] Anlotinib has good efficacy and low toxicity: a phase Ⅱ study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
    Nanlin Hu
    Yiran Si
    Jian Yue
    Tingting Sun
    Xue Wang
    Zhuqing Jia
    Songlin Gao
    Qiao Li
    Yang Shao
    Jiayu Wang
    Yang Luo
    Fei Ma
    Binghe Xu
    Peng Yuan
    Cancer Biology & Medicine, 2021, 18 (03) : 849 - 859
  • [8] Impact of Itraconazole on the Survival of Heavily Pre-treated Patients with Triple-Negative Breast Cancer
    Tsubamoto, Hiroshi
    Sonoda, Takashi
    Inoue, Kayo
    ANTICANCER RESEARCH, 2014, 34 (07) : 3839 - 3844
  • [9] Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
    Hu, Nanlin
    Si, Yiran
    Yue, Jian
    Sun, Tingting
    Wang, Xue
    Jia, Zhuqing
    Gao, Songlin
    Li, Qiao
    Shao, Yang
    Wang, Jiayu
    Luo, Yang
    Ma, Fei
    Xu, Binghe
    Yuan, Peng
    CANCER BIOLOGY & MEDICINE, 2021, 18 (03) : 849 - +
  • [10] Capecitabine monotherapy in pre-treated patients with metastatic breast cancer
    Gennatas, Constantine
    Michalaki, Vasiliki
    Psychogios, John
    Kairi-Vasilatou, E.
    Karvouni, Helen
    Kondi-Paphiti, Agathi
    ANNALS OF ONCOLOGY, 2006, 17 : 86 - 86
12345